Recent developments include completion of FDA enrollment requirements for the pediatric SAVE Registry, ongoing enrollment in the adult NEUTRALIZE-AKI pivotal trial, positive preliminary clinical results, and capital raising activities.

• SeaStar Medical completed the FDA enrollment requirement for the SAVE Surveillance Registry in pediatric AKI patients, enrolling the 50th patient on March 4, 2026, following FDA approval to reduce mandatory enrollment size [N1].
• The company reported positive preliminary results from the SAVE Surveillance Registry showing no device-related safety events and survival rates supporting a 50% reduction in mortality in pediatric AKI patients [N6].
• SeaStar Medical's NEUTRALIZE-AKI pivotal trial for adult AKI patients continues with enrollment of 178 patients as of March 13, 2026, with an independent DSMB recommending continuation and increased sample size [N5].
• The company announced a $4 million direct offering with warrants in a concurrent private placement in July 2025 to support operations and clinical development [N7][N8].
• SeaStar Medical presented its Q3 2025 earnings and business update, highlighting clinical progress and commercialization efforts [N4].
• The company is scheduled to present at the NobleCon21 Investor Conference on December 3, 2025, indicating ongoing investor engagement [N3].
• SeaStar Medical was among biotech and healthcare names leading after-hours gainers in November 2025, reflecting market interest [N2].

SeaStar Medical's SCD therapy addresses a significant unmet need in managing hyperinflammation in critically ill patients, with FDA approval for pediatric use and ongoing pivotal adult trials. Positive early clinical data and multiple Breakthrough Device Designations suggest potential for expanded indications. The therapy's unique mechanism and integration into existing hospital systems could facilitate adoption. Successful commercialization and reimbursement strategies could enable the company to capture a sizable market in acute and chronic inflammatory diseases, potentially transforming treatment paradigms for organ failure.

SeaStar Medical faces substantial financial challenges, including recurring losses, negative cash flows, and substantial doubt about its ability to continue as a going concern without additional financing. Regulatory approval for adult indications remains pending, and commercialization is limited by FDA restrictions under the Humanitarian Device Exemption for pediatric use. The company depends on successful clinical trial outcomes, reimbursement approvals, and scaling manufacturing and sales operations. Risks include potential supply chain disruptions, Nasdaq listing compliance issues, and ongoing shareholder litigation, all of which could materially impact business viability.

SeaStar Medical's moat derives from its proprietary SCD therapy platform, which is protected by a portfolio of 46 patents and exclusive licensing agreements, including with the University of Michigan. The therapy's unique mechanism selectively modulates activated immune cells to address hyperinflammation, a critical unmet medical need with no direct therapeutic alternatives. FDA Humanitarian Device Exemption approval for pediatric AKI and multiple Breakthrough Device Designations for adult indications provide regulatory advantages. The therapy's integration into existing CRRT systems and the company's clinical data demonstrating mortality reduction support its differentiation. However, the moat is challenged by the need for further regulatory approvals, reimbursement establishment, and scaling commercialization.

• Financing and Going Concern Risk: SeaStar has recurring operating losses and negative cash flows, with substantial doubt about its ability to continue as a going concern without securing additional capital. Failure to obtain financing may require restructuring or bankruptcy proceedings.
• Regulatory Approval Risk: The company’s adult SCD therapy is under pivotal clinical trial and requires FDA approval. Failure to obtain regulatory approvals or delays could adversely affect commercialization plans.
• Commercialization and Reimbursement Risk: Limited revenue to date and restrictions under the pediatric HDE approval constrain sales. Achieving reimbursement from CMS and private payors is critical but uncertain, impacting market adoption and financial performance.
• Supply Chain and Manufacturing Risk: SeaStar relies on third-party suppliers and manufacturing partners. Disruptions in supply of critical components or intravenous solutions could negatively impact product availability and clinical trial progress.
• Nasdaq Listing Compliance Risk: The company has faced Nasdaq notifications for noncompliance with listing standards, including minimum bid price and stockholders’ equity requirements, posing risks of delisting that could affect liquidity and capital raising.
• Litigation Risk: SeaStar is subject to shareholder derivative and class-action litigation related to prior financial restatements, which could result in legal costs and reputational damage.

• SeaStar Medical Holding Corp is a commercial-stage healthcare company focused on treatments for critically ill patients with organ failure, primarily using its Selective Cytopheretic Device (SCD) therapy.
• The SCD is a disease-modifying device designed to neutralize overactive immune cells and stop cytokine storms causing hyperinflammation, with applications in acute and chronic kidney disease, cardiovascular, and other inflammatory diseases.
• The company received FDA Humanitarian Device Exemption (HDE) approval for its pediatric SCD therapy (QUELIMMUNE) on February 21, 2024, the only FDA-approved product for pediatric patients with acute kidney injury (AKI) due to sepsis requiring kidney replacement therapy.
• Commercial shipments of QUELIMMUNE began in July 2024, targeting top-tier pediatric medical facilities.
• The FDA requires a post-approval patient surveillance registry (SAVE Surveillance Registry) to track safety and performance metrics; as of December 31, 2025, 10 active commercial hospital customers had completed the registry process and purchased QUELIMMUNE.
• Early real-world data from 21 pediatric patients in the SAVE Registry showed no device-related safety events, with 76% survival at 60 days and 71% at 90 days, supporting a 50% reduction in mortality compared to historical data.
• In December 2025, the FDA approved reducing the mandatory enrollment size of the SAVE Registry from 300 to 50 patients; the 50th patient was enrolled on March 4, 2026.
• SeaStar is conducting a pivotal clinical trial (NEUTRALIZE-AKI) for adult patients with AKI receiving continuous renal replacement therapy (CRRT); as of March 13, 2026, 178 of 339 planned patients were enrolled.
• The NEUTRALIZE-AKI trial's primary endpoint is a composite of 90-day mortality or dialysis dependency comparing SCD plus CRRT versus CRRT alone.
• The company has received six FDA Breakthrough Device Designations (BDD) covering multiple adult indications including AKI, cardiorenal syndrome, hepatorenal syndrome, end-stage renal disease, and systemic inflammatory response during cardiac surgery.
• SeaStar's SCD therapy uses regional citrate anticoagulation (RCA) to create a low calcium environment that modulates activated neutrophils and monocytes, reducing hyperinflammation without causing immunosuppression.
• The company has a patent portfolio of 46 patents and 1 pending application, including exclusive licenses from the University of Michigan for commercialization rights.
• SeaStar uses a direct sales model for QUELIMMUNE and has built internal sales and marketing infrastructure focused on pediatric hospitals.
• The company is developing reimbursement strategies with CMS and private payors to support future adult SCD product sales.
• SeaStar has positive working capital of $9.8 million as of December 31, 2025, with cash and equivalents of $51,567 and current assets of $13.58 million against current liabilities of $3.74 million, yielding a current ratio of 3.63.
• The company reported a net loss of $12.15 million for the year ended December 31, 2025, and a basic EPS of -$5.86 for the same period.
• SeaStar has recurring operating losses and negative cash flows, with substantial doubt about its ability to continue as a going concern without additional financing.
• The company completed a $4 million registered direct offering and concurrent private placement of common stock and warrants in July 2025.
• SeaStar's management team has extensive healthcare industry experience, including regulatory, commercialization, and medical affairs expertise.
• The company faces risks including the need for additional capital, regulatory approval uncertainties, potential supply chain disruptions, and risks related to Nasdaq listing compliance.
• SeaStar's SCD therapy has potential to address a large market of over one million patients annually with life-threatening hyperinflammatory conditions.
• The company is expanding clinical development opportunities in pediatric and adult indications based on unmet medical needs and FDA BDD awards.
• SeaStar terminated a distribution agreement with Nuwellis and now sells QUELIMMUNE directly.
• The company is focused on scaling production with manufacturing partners to meet anticipated demand for its SCD therapy.
• SeaStar's SCD therapy is designed to integrate easily into existing CRRT systems used in ICUs and has potential for integration into chronic kidney disease dialysis systems.
• The company is conducting feasibility studies for SCD therapy in adult patients with cardiorenal syndrome awaiting left ventricular assist device implantation.
• SeaStar is pursuing business development and out-licensing opportunities with major medical and pharmaceutical companies to expand its market reach.
• The company faces risks related to potential restructuring or bankruptcy proceedings if additional financing is not secured.
• SeaStar's clinical data suggest a 50% reduction in mortality for patients treated with SCD therapy compared to historical controls.
• The company is subject to risks from potential shareholder litigation related to prior financial restatements.